Use of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

被引：0
|
作者：
Elkerm, Y.
Ali, I. M.
Elsaid, A. A.
机构：
[1] Univ Alexandria, Med Res Inst, Alexandria, Egypt
[2] Univ Alexandria, Fac Med, Alexandria, Egypt
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e11101
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11101
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer.
    Lang, I.
    Bell, R.
    Feng, F.
    Lopez, R. I.
    Jassem, J.
    Semiglazov, V.
    Al-Sakaff, N.
    Carreras, E.
    Chang, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
  • [3] Trastuzumab after adjuvant chemotherapy: survival benefit in HER2-positive breast cancer
    [J]. Nature Clinical Practice Oncology, 2007, 4 (4): : 208 - 209
  • [4] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [5] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
  • [6] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [7] Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer
    Hudis, CA
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 12 - 13
  • [8] Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer
    Clifford A Hudis
    [J]. Nature Clinical Practice Oncology, 2006, 3 : 12 - 13
  • [9] Adjuvant Trastuzumab in HER2-Positive Breast Cancer REPLY
    Slamon, Dennis J.
    Buyse, Marc
    Press, Michael F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 663 - 665
  • [10] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345